Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Marchex Inc (MCHX): Prescott Group Capital Management Raises Its Stake

Phil Frohlich‘s Prescott Group Capital Management recently reported increasing its stake in Marchex Inc (NASDAQ:MCHX) to 4.04 million Class B Common Shares that represent 10.6% of the outstanding stock, according to a recent 13G filing with the US Securities and Exchange Commission. Previously, the fund’s stake consisted of 1.79 million Class B Shares held at the end of June.

Marchex is a mobile advertising analytics company, which offers professional services for businesses that depend on consumer calls to drive sales. Over the past 12 months, the company’s stock has lost 29.29%. In its latest financial report for the second quarter of 2016, the company disclosed a loss per share of $0.02, in line with estimates, and revenue of $34.41 million, missing the estimates of $35 million. Recently, Roth Capital reiterated its rating on Marchex’ stock, and downgraded it to ‘Neutral’ from ‘Buy’.

stocks, analysis, market, numbers, business, ticker, trade, money, price, investment, index, chart


The number of investors bullish on Marchex (NASDAQ:MCHX) decreased by two recently, and at the end of June, there were 10 smart money managers long the stock.  Among them were Mark Coe’s Coe Capital Management, which held a position valued at $205.24 million, Constantinos J. Christofilis’ Archon Capital Management, with a position worth around $6.82 million, Jim Simons’ Renaissance Technologies, Joseph Mathias’ Concourse Capital Management, and Chuck Royce’s Royce & Associates.

Among investors who lost enthusiasm for investing in Marchex (NASDAQ:MCHX) and decide to sell their positions were Peter Algert And Kevin Coldiron’s Algert Coldiron Investors, which said goodbye to $474,000, and Israel Englander’s Millennium Management, which dropped a position valued at the end of March at $65,000.

Follow Marchex Inc (NASDAQ:MCHX)
Trade (NASDAQ:MCHX) Now!

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Prescott Group Capital Management 4,038,353 0 4,038,353 0 4,038,353 10.6%
Prescott Group Aggressive Small Cap 0 4,038,353 0 4,038,353 4,038,353 10.6%
Prescott Group Aggressive Small Cap II 0 4,038,353 0 4,038,353 4,038,353 10.6%
Phil Frohlich 4,038,353 0 4,038,353 0 4,038,353 10.6%

Phil Frohlich
Phil Frohlich
Prescott Group Capital Management

Page 1 of 9 – SEC Filing


Washington, DC 20549




(Rule 13d-102)






Marchex, Inc.

(Name of Issuer)

Class B Common Stock, $0.01 par value per share

(Title of Class of Securities)


(CUSIP Number)

August 31, 2016

(Date of Event Which Requires Filing of this Statement)



Check the
appropriate box to designate the rule pursuant to which this Schedule is filed:

x Rule

¨ Rule 13d-1(c)

¨ Rule 13d-1(d)

Follow Marchex Inc (NASDAQ:MCHX)
Trade (NASDAQ:MCHX) Now!

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.